Bradykinin Potentiation by Angiotensin-(1-7) and ACE Inhibitors Correlates With ACE C- and N-Domain Blockade

Beril Tom, René de Vries, Pramod R. Saxena, A.H. Jan Danser

Abstract—ACE inhibitors block B2 receptor desensitization, thereby potentiating bradykinin beyond blocking its hydrolysis. Angiotensin (Ang)-(1-7) also acts as an ACE inhibitor and, in addition, may stimulate bradykinin release via angiotensin II type 2 receptors. In this study we compared the bradykinin-potentiating effects of Ang-(1-7), quinaprilat, and captopril. Porcine coronary arteries, obtained from 32 pigs, were mounted in organ baths, preconstricted with prostaglandin F2α, and exposed to quinaprilat, captopril, Ang-(1-7), and/or bradykinin. Bradykinin induced complete relaxation (pEC50 = 8.11 ± 0.07, mean ± SEM), whereas quinaprilat, captopril, and Ang-(1-7) alone were without effect. Quinaprilat shifted the bradykinin curve to the left in a biphasic manner: a 5-fold shift at concentrations that specifically block the C-domain (0.1 to 1 nmol/L) and a 10-fold shift at concentrations that block both domains. Captopril and Ang-(1-7) monophasically shifted the bradykinin curve to the left, by a factor of 10 and 5, respectively. A 5-fold shift was also observed when Ang-(1-7) was combined with 0.1 nmol/L quinaprilat. Repeated exposure of porcine coronary arteries to 0.1 μmol/L bradykinin induced B2 receptor desensitization. The addition of 10 μmol/L quinaprilat or Ang-(1-7) to the bath, at a time when bradykinin alone was no longer able to induce relaxation, fully restored the relaxant effects of bradykinin. Angiotensin II type 1 or 2 receptor blockade did not affect any of the observed effects of Ang-(1-7). In conclusion, Ang-(1-7), like quinaprilat and captopril, potentiates bradykinin by acting as an ACE inhibitor. Bradykinin potentiation is maximal when both the ACE C- and N-terminal domains are inhibited. The inhibitory effects of Ang-(1-7) are limited to the ACE C-domain, raising the possibility that Ang-(1-7) synergistically increases the blood pressure-lowering effects of N-domain–specific ACE inhibitors. (Hypertension. 2001;38:95-99.)

Key Words: angiotensin | bradykinin | angiotensin-converting enzyme inhibitors | receptors, bradykinin | coronary artery

Angiotensin (Ang)-(1-7) is a heptapeptide that is formed endogenously from both Ang I and Ang II.1 In rats and dogs, Ang-(1-7) exerts direct vasodilatory effects via non–angiotensin II type 1 (AT1), non–angiotensin II type 2 (AT2) receptors, possibly by stimulating bradykinin and NO release.1,2 In contrast, in humans or pigs, no direct vasodilatory effects of Ang-(1-7) were observed,3–7 although Ang-(1-7) did antagonize the pressor effects of Ang II, suggesting that it may cause vasodilation indirectly, by acting as an AT1 receptor antagonist.5,6 In addition, Ang-(1-7) potentiates bradykinin, either via an AT2 receptor–dependent mechanism or through inhibition of ACE.3,5,8 The latter effect is not necessarily based on blockade of bradykinin hydrolysis, because recent studies have shown that ACE inhibitors, including Ang-(1-7), potentiate bradykinin by inhibiting desensitization of its receptor.9–11 Somatic ACE has 2 homologous domains, each containing an active center. According to their position (N- or C-terminal), these domains are designated as the N- or C-domain, respectively. Interestingly, Ang-(1-7) inhibits the C-domain more potently than the N-domain (by 1 order of magnitude)8 and is cleaved to Ang-(1-5) by the N-domain.12

In the present study, we investigated the bradykinin-potentiating effects of Ang-(1-7) in porcine coronary arteries (PCAs), its dependency on ACE, and the possible involvement of AT1 and/or AT2 receptors. The effects of Ang-(1-7) were compared with those of quinaprilat and captopril, 2 ACE inhibitors with preference for the ACE C- and N-terminal domains, respectively.13,14 We also verified the effect of Ang-(1-7) in human coronary arteries (HCAs).

Methods

Tissue Collection

HCAs were obtained from 4 “heart beating” organ donors (2 men and 2 women; age range, 14 to 38 years; mean±SEM age, 23±5 years) who died of noncardiac causes (1 subarachnoid bleeding, 3 head trauma) <24 hours before the heart was taken to the laboratory. Hearts were provided by the Rotterdam Heart Valve Bank (Bio Implant Services/Eurotransplant Foundation, Rotterdam, The Netherlands) after removal of the aortic and pulmonary valves for transplantation purposes. The study was approved by the joint ethics committee of Erasmus University Rotterdam and University Hospital Rotterdam. Immediately after circulatory arrest, the hearts were stored in an ice-cooled, sterile, organ-protecting solution. After...
arrival in the laboratory, the HCAs were removed and stored overnight in a cold, oxygenated Krebs’ bicarbonate solution of the following composition (mmol/L): NaCl 118, KCl 4.7, CaCl 2.5, MgSO 4 1.2, KH 2 PO 4 1.2, NaHCO 3 25, and glucose 8.3 (pH 7.4). Vessels were then cut into segments of ~4 mm in length, suspended on stainless steel hooks in 15-mL organ baths containing Krebs’ bicarbonate solution, aerated with 95% O 2 /5% CO 2 , and maintained at 37°C. Segments containing macroscopically visible atherosclerotic lesions were not used.

PCAs were obtained from 32 pigs age 2 to 3 months (Yorkshire×Landrace; weight, 10 to 15 kg). The pigs had been used in in vivo experiments studying the effects of α-adrenoceptor and serotonin receptor agonists and antagonists under pentobarbital (600 mg IV) anesthesia. The ethics committee of Erasmus University Rotterdam dealing with the use of animals for scientific experiments approved the protocol for this investigation. Hearts were explanted at the end of the experiment, and the coronary arteries were removed immediately and handled in the same way as HCAs.

Organ Bath Studies

All vessel segments were allowed to equilibrate for at least 30 minutes, and the organ bath fluid was refreshed every 15 minutes during this period. Changes in tissue contractile force were recorded with a Harvard isometric transducer. The vessel segments, stretched to a stable force of ~15 mN, were exposed to 30 mmol/L K+ twice. The functional integrity of the endothelium was verified by observing relaxation to 1 mmol/L substance P after preconstriction with 1 mmol/L prostaglandin F 2α (PGF 2α). Subsequently, the tissue was exposed to 100 mmol/L K+ to determine the maximal contractile response to K+. The segments were then allowed to equilibrate in fresh organ bath fluid for 30 minutes. Thereafter, the following experiments were performed.

First, Ang-(1-7) concentration-response curves (CRCs) (0.1 nmol/L to 10 μmol/L) were constructed in HCAs and PCAs, both at baseline and after preconstriction with 10 μmol/L PGF 2α, in the absence or presence of the AT 1 receptor antagonist irbesartan (1 μmol/L) or the AT 2 receptor antagonist PD 123,319 (1 μmol/L). Second, the effects of Ang-(1-7), quinaprilat, and captopril on bradykinin-induced vasorelaxation were studied in PCAs. Vessels were preincubated for 30 minutes in the absence or presence of Ang-(1-7) (10 pmol/L to 10 μmol/L), quinaprilat (0.1 μmol/L to 0.1 mmol/L), captopril (0.1 μmol/L to 0.1 mmol/L), 10 μmol/L Ang-(1-7)+1 μmol/L irbesartan, 10 μmol/L Ang-(1-7)+1 μmol/L PD 123,319, 10 μmol/L Ang-(1-7)+0.1 μmol/L quinaprilat, or 10 μmol/L Ang-(1-7)+10 μmol/L quinaprilat. Vessels were then preconstricted with 10 μmol/L PGF 2α, or 1 μmol/L U46619, and CRCs to bradykinin (0.1 mmol/L to 1 μmol/L) were constructed.

Third, the effect of quinaprilat and Ang-(1-7) on desensitized B 2 receptors was studied in PCAs. Vessels were preincubated for 30 minutes with or without 1 μmol/L irbesartan or 1 μmol/L PD 123,319. Vessels were then preconstricted with 10 μmol/L PGF 2α and exposed 3 times to a concentration of bradykinin (0.1 μmol/L) that is capable of inducing maximal relaxation. Each next exposure was started as soon as the effect of the previous exposure had disappeared, ie, after ~15 minutes. After the third exposure, when bradykinin no longer exerted a vasodilatory effect, quinaprilat (10 μmol/L) or Ang-(1-7) (10 μmol/L) was added to the organ bath. Thereafter, when the effects of quinaprilat and Ang-(1-7) had disappeared, a fourth bradykinin dose (0.1 μmol/L) was added to the organ bath.

Statistical Analysis

Data are given as mean±SEM and expressed as a percentage of the contraction in response to PGF 2α or U46619. CRCs were analyzed by the logistic function described by de Lean et al 17 to obtain pEC 50 (−log EC 50 ) values, EC 50 representing the concentration at which 50% of the maximal relaxant effect has been reached. Statistical analysis was by ANOVA, followed by post hoc evaluation (according to Tukey or Dunnett where appropriate). Values of P<0.05 were considered significant.

Results

Effect of Ang-(1-7) on HCAs and PCAs

Ang-(1-7), at concentrations up to 10 μmol/L, did not exert a response in HCAs (n=4) and PCAs (n=5 to 12) at baseline or after preconstriction with PGF 2α, or in the presence of irbesartan or PD 123,319.

Effects of Ang-(1-7), Quinaprilat, and Captopril on Bradykinin-Induced Relaxation in PCAs

Bradykinin caused complete relaxation of preconstricted PCAs in a concentration-dependent–manner (pEC 50 =8.11±0.07; n=12; Figure 1, top panel). Quinaprilat (10 μmol/L) and captopril (10 μmol/L), like Ang-(1-7) at this concentration, did not exert any effect on preconstricted PCAs. However, in the presence of 10 μmol/L Ang-(1-7), the bradykinin CRC was shifted ~5-fold to the left (pEC 50 =8.72±0.09; n=12; P<0.05 versus control), whereas in the presence of 10 μmol/L quinaprilat or 10 μmol/L captopril the bradykinin CRC was shifted ~10-fold to the left (pEC 50 =9.03±0.21 and 8.91±0.09, respectively; n=8; P<0.01 versus control) (Figure 1, top panel). The effect of Ang-(1-7) on the bradykinin CRC was not affected by irbesartan or PD 123,319 (Figure 1, bottom panel).

To study the concentration dependency of the Ang-(1-7)– and ACE-inhibitor–induced leftward shifts, bradykinin CRCs

Figure 1. Relaxations of PCAs, preconstricted with 10 μmol/L PGF 2α or 1 μmol/L U46619, to bradykinin in the absence (control) or presence of 10 μmol/L Ang-(1-7), 10 μmol/L quinaprilat, or 10 μmol/L captopril (top). The effect of Ang-(1-7) on bradykinin-induced relaxations was also studied in the presence of 1 μmol/L irbesartan or 1 μmol/L PD 123,319 (bottom). Data (mean±SEM of 5 to 12 experiments) are expressed as a percentage of the contraction induced by PGF 2α or U46619. Ang-(1-7), quinaprilat, and captopril significantly shifted the bradykinin CRC to the left (P<0.05 vs control for Ang-(1-7); P<0.01 vs control for the 2 ACE inhibitors), and the effect of Ang-(1-7) was not influenced (P=NS) by the presence of irbesartan or PD 123,319.
were also constructed in the presence of a wide range of Ang-(1-7), quinaprilat, and captopril concentrations (Figure 2). The leftward shift caused by quinaprilat occurred in a biphasic manner, with a 5-fold shift at concentrations in the subnanomolar range and a 10-fold shift at concentrations >1 nmol/L. This biphasic shift is in agreement with earlier studies demonstrating different quinaprilat binding affinities of the ACE C- (Kd = 7 pmol/L) and N-domains (Kd = 1267 pmol/L) and suggests that the 5- and 10-fold shifts represent C-domain inhibition and complete (ie, C- plus N-domain) ACE inhibition, respectively. The 10-fold leftward shift caused by captopril occurred monophasically (Figure 2), suggesting that captopril is bound with similar affinity by the 2 ACE domains. The 5-fold leftward shift caused by Ang-(1-7) also occurred monophasically (Figure 2), suggesting either that Ang-(1-7) inhibits 1 ACE domain only or that Ang-(1-7) potentiates bradykinin independently of its effects on ACE. To sort out the latter, the effect of 10 μmol/L Ang-(1-7) on top of quinaprilat, either at a concentration that selectively inhibits the ACE C-domain (0.1 nmol/L) or at a concentration that inhibits both ACE domains (10 μmol/L), was studied. Ang-(1-7) affected neither the 5-fold leftward shift of the bradykinin CRC at 0.1 nmol/L quinaprilat (pEC50 = 8.59 ± 0.39 and 8.68 ± 0.29 with and without Ang-(1-7), respectively; n = 13; P = NS) nor the 10-fold shift at 10 μmol/L quinaprilat (pEC50 = 9.06 ± 0.20 and 9.03 ± 0.21 with and without Ang-(1-7), respectively; n = 11; P = NS) (Figure 3). Most likely, therefore, Ang-(1-7), at concentrations up to 10 μmol/L, acts as a selective inhibitor of the ACE C-domain.

**Effect of Ang-(1-7) and Quinaprilat on Desensitized B2 Receptors in PCAs**

Repeated exposure of preconstricted vessel segments to 0.1 μmol/L bradykinin produced progressively smaller responses (Figure 4, top panel). The response to the third bradykinin dose was <50% of the response to the first bradykinin dose. Quinaprilat or Ang-(1-7), added to the organ bath after the effect of the third bradykinin dose had disappeared, both at a concentration of 10 μmol/L, completely restored the relaxant effect of bradykinin (90 ± 10% and 83 ± 8% relaxation, respectively; n = 8; P = NS). A fourth bradykinin dose, added after the effect of quinaprilat or Ang-(1-7) had disappeared, induced no further effect. The effect of Ang-(1-7) was not different in the presence of irbesartan or PD 123,319 (Figure 4, bottom panel).

**Discussion**

The present study shows that Ang-(1-7) potentiates the vasodilator effects of bradykinin in PCAs through inhibition of the ACE C-domain. AT1 or AT2 receptors are not involved in this effect, nor did Ang-(1-7) exert direct (ie, independently of bradykinin) relaxant effects in either HCA or PCAs. Furthermore, the maximal potentiating effect of Ang-(1-7) was smaller than that of the ACE inhibitors quinaprilat and captopril, suggesting that full potentiation will only be obtained when both ACE domains are inhibited.

The concentrations of Ang-(1-7) required to obtain ACE C-domain inhibition (≥1 μmol/L) are in agreement with previously reported values. These concentrations exceed the in vivo tissue and plasma Ang-(1-7) concentrations in rats and humans by at least 4 orders of magnitude. Ang-(1-7)
Ang-(1-7). However, the fact that most ACE inhibitors also inhibit the ACE N-domain–mediated degradation of bradykinin. In contrast, using the ACE inhibitor quinaprilat, which binds to the ACE C-domain with almost 200-fold greater affinity than to the ACE N-domain, we could make such a distinction: quinaprilat shifted the bradykinin CRC to the left in a biphasic manner, with an ≈5-fold shift occurring at concentrations that selectively block the C-domain and an ≈10-fold shift at concentrations that block both domains. Our inability to find a similar biphasic shift in the presence of increasing concentrations of captopril most likely relates to the limited selectivity of this ACE inhibitor for the ACE N-domain.

Ang-(1-7), like captopril, induced a monophasic leftward shift of the bradykinin CRC. At the highest Ang-(1-7) concentration (10 μmol/L) that was tested, however, the shift was only half of that caused by similar concentrations of quinaprilat or captopril. Adding quinaprilat, at a concentration that selectively blocks the ACE C-domain, to 10 μmol/L Ang-(1-7) did not cause a further leftward shift, thereby demonstrating that Ang-(1-7), at least at this concentration, blocks the ACE C-domain only. Because a concentration of 10 μmol/L is already many orders of magnitude above the measured concentrations of Ang-(1-7) in vivo, we did not evaluate whether even higher concentrations of Ang-(1-7) resulted in ACE N-domain inhibition.

Does ACE inhibition result in bradykinin potentiation by blocking its hydrolysis? Because bradykinin, like Ang I, is cleaved equally well by the 2 ACE domains, our finding that blockade of both domains results in a twice as large leftward shift as blockade of 1 domain appears to support this possibility. However, the long half-life of bradykinin in this preparation (30 minutes), as well as our previous finding in PCAs that the quinaprilat-induced leftward shift of the ACE-resistant bradykinin analogue [Hyp³-Tyr(Me)⁸]-bradykinin was not different from that of bradykinin, argues against this concept. Moreover, under conditions of B₂ receptor desensitization (induced by repeated exposure to a concentration of bradykinin that causes maximal relaxation), when bradykinin itself was no longer active, both quinaprilat and Ang-(1-7) immediately restored the effect of bradykinin. Taken together, therefore, a more likely explanation for the Ang-(1-7)–, quinaprilat–, and captopril-induced bradykinin potentiation is the upregulation (or resensitization) of B₂ receptors that has recently been described in Chinese hamster ovary (CHO) cells transfected with the human B₂ receptor and human ACE. This effect only occurs when ACE and B₂ receptors are sterically closely associated, probably forming a heterodimer. ACE inhibitors are believed to alter the heterodimer interaction, thereby promoting a conformation in the B₂ receptor that affects its sequestration and coupling to second messengers. Our findings in intact PCAs show that ACE-B₂ receptor crosstalk is not limited to transducing the human B₂ receptor and human ACE. This effect only occurs when ACE and B₂ receptors are sterically closely associated, probably forming a heterodimer. ACE inhibitors are believed to alter the heterodimer interaction, thereby promoting a conformation in the B₂ receptor that affects its sequestration and coupling to second messengers. ACE inhibitors are believed to alter the heterodimer interaction, thereby promoting a conformation in the B₂ receptor that affects its sequestration and coupling to second messengers.

**References**


Bradykinin Potentiation by Angiotensin-(1-7) and ACE Inhibitors Correlates With ACE C- and N-Domain Blockade
Beril Tom, René de Vries, Pramod R. Saxena and A.H. Jan Danser

_Hypertension_. 2001;38:95-99
doi: 10.1161/01.HYP.38.1.95

_Hypertension_ is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2001 American Heart Association, Inc. All rights reserved.
Print ISSN: 0194-911X. Online ISSN: 1524-4563

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://hyper.ahajournals.org/content/38/1/95

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in_Hypertension_ can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to_Hypertension_ is online at:
http://hyper.ahajournals.org//subscriptions/